Loading organizations...
§ Private Profile · Salt Lake City, UT, USA
Medical device company developing wearable, wireless EEG technology, focused on seizure detection for hospital emergency and critical care.
Based in Salt Lake City, Utah, Epitel develops wearable, wireless, and non-invasive electroencephalogram technology for seizure detection and broader neurological monitoring. The company's flagship product, REMI, is an AI-enabled monitoring platform designed to expand diagnostic capabilities within hospital emergency departments and critical care units following FDA clearance in 2021. To support its commercialization and platform development, the medical device manufacturer has secured over $20 million in total funding, which includes $7.5 million in early grant funding from organizations like the Epilepsy Foundation. Additionally, the enterprise raised a $12.5 million Series A financing round backed by institutional investors such as Catalyst Health Ventures, Genoa Ventures, Dexcom, and OSF Ventures. Founded in 2007 by Mark Lehmkuhle, who now serves as Chief Technology Officer, Epitel is currently guided by Chief Executive Officer Steve Pacelli and Executive Chairman Andy Rasdal.
Epitel has raised $13.0M across 1 funding round.
Epitel has raised $13.0M in total across 1 funding round.
Epitel has raised $13.0M in total across 1 funding round.
Epitel's investors include Genoa Ventures, Joshua Phillips, Andy Rasdal, MedMountain Ventures, OSF Ventures, Salt Lake City Angels, Wavemaker Three-Sixty Health.
Epitel has raised $13.0M across 1 funding round. Most recently, it raised $13.0M Series A in February 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 1, 2022 | $13M Series A | Genoa Ventures, Joshua Phillips | Andy Rasdal, MedMountain Ventures, OSF Ventures, Salt Lake City Angels, Wavemaker Three Sixty Health | Announced |
Epitel is a digital health technology company specializing in wireless, wearable EEG (electroencephalogram) monitoring systems designed to revolutionize brain health monitoring, particularly for epilepsy patients. Their flagship product, the REMI Remote EEG Monitoring System, enables long-term, high-fidelity seizure detection outside traditional clinical settings by combining disposable sensors, cloud-based data analytics, and AI-driven event detection. This system serves healthcare professionals and patients by providing accurate, real-time seizure monitoring in both ambulatory and healthcare environments, addressing the limitations of traditional wired EEG systems. Epitel has demonstrated growth momentum through significant funding rounds and expanding proprietary EEG seizure monitoring databases[1][2][3][4].
Founded in 2014 by Mark Lehmkuhle, PhD, Epitel emerged from the need to improve EEG monitoring by making it wireless, more accessible, and patient-friendly. The idea originated to overcome the cumbersome nature and limited mobility of traditional EEG setups, which often delay critical neurological monitoring. Early traction included developing the REMI system, which allows rapid setup and continuous monitoring for up to 30 days using disposable sensors, a pivotal advancement in remote neurological care. The company has since evolved to integrate advanced AI algorithms (REMI Vigilenz) for seizure event detection and has raised over $12.5 million in Series A funding to scale its technology[2][3][4].
Epitel rides the growing trend of digital health innovation and remote patient monitoring, particularly in neurology. The timing is critical as healthcare increasingly shifts towards decentralized, patient-centric models that leverage wearable technology and AI to improve outcomes and reduce hospital stays. Market forces such as rising epilepsy prevalence, demand for continuous neurological monitoring, and advances in cloud computing and machine learning favor Epitel’s solutions. By enabling accurate, ambulatory EEG monitoring, Epitel influences the broader ecosystem by setting new standards for seizure detection, reducing barriers to care, and supporting telehealth expansion in neurology[1][3][4].
Epitel is poised to expand its impact by further refining AI algorithms, scaling its proprietary EEG database, and broadening clinical adoption globally. Future trends shaping its journey include increased integration of AI in diagnostics, regulatory acceptance of remote monitoring technologies, and growing demand for personalized neurological care. As Epitel advances, it may influence broader neurological disease management beyond epilepsy, potentially transforming how brain health is monitored and managed in real time. Its leadership in wireless EEG technology positions it well to capitalize on the convergence of wearable tech, AI, and cloud healthcare solutions[1][2][3][4].